<DOC>
	<DOCNO>NCT00562055</DOCNO>
	<brief_summary>This study compare safety efficacy [ S , S ] -reboxetine atomoxetine treatment adult patient attention deficity-hyperactivity disorder .</brief_summary>
	<brief_title>Double-Blind , Four Week Trial Of S , S-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>1 . Diagnosis Attention Deficit Hyperactivity Disorder accord DSMIV criterion . 2 . Score 24 high Adult ADHD Investigator Symptom Rating Scale 3 . Score 4 high Clinician Global Impression Severity scale 1 . Significant comorbid psychiatric diagnose 2 . Significant risk suicidal violent behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>